Quantcast
Home > Quotes > RVNC
RVNC

Revance Therapeutics, Inc. Common Stock (RVNC) Quote & Summary Data

$20.7
*  
1.23
5.61%
Get RVNC Alerts
*Delayed - data as of Dec. 13, 2018  -  Find a broker to begin trading RVNC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 22.19 / $ 20.64
Share Volume
355,772
50 Day Avg. Daily Volume
256,272
Previous Close
$ 21.93
52 Week High / Low
$ 37.45 / $ 19.617
Market Cap
765,644,707
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
355,772
50 Day Avg. Daily Volume:
256,272

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.96

Trading Range

The current last sale of $20.70 is 5.52% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 22.19 $ 37.45
 Low: $ 20.64 $ 19.617

Company Description (as filed with the SEC)

Revance Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. We are leveraging our proprietary portfolio of botulinum toxin type A compounds, formulated with our patented and proprietary peptide technology, to address unmet needs in large and growing neuromodulator markets. Our proprietary peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical. We are pursuing clinical development for RT002 injectable in a broad spectrum of aesthetic and therapeutic indications and are planning to conduct additional preclinical development of our topical program. Neither of our product candidates contains albumin or any other animal or human-derived materials.  ... More ...  


Risk Grade

Where does RVNC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 21.95
Open Date:
Dec. 13, 2018
Close Price:
$ 20.70
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info